Metformin is thought to have an anorexic effect partly by promoting the secretion of GLP-1 and activating afferent inputs from the intestinal tract to the NTS [24], but there is currently no evidence that the degree of weight loss exceeds 5%, which is the standard for use as an anti-obesity drug. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.